Key result
Revascularization with drug-eluting stents for unprotected left main trunk disease significantly reduces the need for target lesion revascularization compared to bare metal stents without increasing the risk of stent thrombosis, myocardial infarction, or cardiac death.
Why the study?
Does percutaneous coronary intervention with drug-eluting stents reduce target lesion revascularization compared to bare metal stents in patients with unprotected left main trunk disease?
Does percutaneous coronary intervention with drug-eluting stents reduce target lesion revascularization compared to bare metal stents in patients with unprotected left main trunk disease?
PCI with drug-eluting stents for unprotected left main trunk disease significantly reduces the need for repeat revascularization compared to bare metal stents, without an increased risk of death, myocardial infarction, or stent thrombosis.
Coronary artery bypass grafting has long been considered the standard revascularization treatment for unprotected left main trunk disease (ULMTD). Percutaneous coronary intervention (PCI) with bare metal stent (BMS) was performed on patients for whom coronary artery bypass grafting was a high risk or those selected by lesion anatomy such as large simple ostial or body lesion. However, its clinical indication is limited by the high rate of target lesion revascularization (TLR). PCI with drug-eluting stent (DES) is increasingly being performed because of its lower TLR rate. Randomized and meta-analysis studies demonstrate that PCI with DES for ULMTD, compared with BMS, could be more strongly associated with a significant reduction in the need for TLR without any additional adverse outcomes, although it has some limitations on indications.
No takes yet. Share an insight, caveat, or question.
Kadota et al. (2011) conducted a review in Unprotected left main trunk disease (ULMTD). Drug-eluting stent (DES) vs. Bare metal stent (BMS) was evaluated. Revascularization with drug-eluting stents for unprotected left main trunk disease significantly reduces the need for target lesion revascularization compared to bare metal stents without increasing the risk of stent thrombosis, myocardial infarction, or cardiac death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: